Trials / NCT06646289
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
Underway, not enrolling Phase 2 Gene therapy
- Sponsor
- MeiraGTx Ocular UK Ltd
- Treatment
- AAV5-hRKp.RPGR; No intervention (Follow-Up assessment)
- Gene
- RPGR
- Conditions
- X-Linked Retinitis Pigmentosa
- Ages
- 5 Years to no upper limit
- Enrollment
- 24 participants
- Started
- 2024-10-10
- Main results expected
- 2030-10-24
- Results posted
- Not yet
- Record last updated
- 2026-09-25
What the study is testing
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
Where it runs
United Kingdom (1)
- Moorfields Eye Hospital, London
United States (2)
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
- University of Michigan Kellogg Eye Center, Ann Arbor, Michigan